Nitinol Medical Technologies Announces Agreement With CS Fluids

Nitinol Medical Technologies announced that its neurosurgery division, NMT Neurosicences, has signed an agreement with CS Fluids to cooperatively develop and manufacture a shunt device designed specifically to treat Alzheimer's Disease.

Under the terms of the agreement, NMT Neurosciences will work with CS Fluids to utilize NMT's patented shunt technology to develop, manufacture, and clinically evaluate a shunt device with parameters specific to the Alzheimer's population. If the device proves clinically useful, NMT Neurosciences has first rights of negotiation for distribution of the device following regulatory approvals.

CS Fluids, a venture funded startup, has initiated IDE approved clinical studies at Stanford University to examine the effects of utilizing cerebral spinal fluid shunting in patients with Alzheimer's Disease. Preliminary results of this study have been encouraging, and expanded trials are planned using the NMT Neurosciences shunt technology.